A new act is coming in to swoop up Concert Pharmaceuticals’ audience as the biotech sells some central nervous system assets to little known startup Terran Biosciences. Terran CEO Sam Clark, M.D., PhD, and Chief Business Officer Dustin Tetzl, M.D., declined to disclose which assets were bought in an interview with Fierce Biotech.
Category Press Release
Published in Fierce Biotech